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In this issue of the Journal, we are presented with a report by Barone-Rochette et al., of the diagnostic accuracy of a novel approach to myocardial perfusion imaging for stable coronary artery disease (CAD). 1 The protocol utilized was dual isotope, stress thallium-201/ rest Tc-99m. The dose was 2 mCi of Tl-201, and around 8 mCi of Tc-99m sestamibi for patients \ 80 Kg, and weight-based for heavier patients, resulting in an average total body effective dose of 12 mSv. Strengths of the study include the use of FFR, and not just visually interpreted coronary angiography as the comparator standard, and the fact that all patients were referred for coronary angiography. While the latter fact avoids the verification bias resulting from selective angiography in patients with abnormal scans, it introduces a bias of its own by selecting only high-risk patients as subjects for the study. This selection bias was reflected in the results, with reported patient-level sensitivity, specificity, and diagnostic accuracy of 92.8%, 69.2%, and 81.4%, respectively.
The protocol is novel in that it used the strengths of solid-state (Cadmium Zinc Telluride-crystal) technology to enable low-dose imaging with Tl-201, a tracer that has a higher extraction fraction than Tc-99m sestamibi or Tc-99m tetrofosmin, and thus might be expected to improve the sensitivity of detecting mild disease and identify more ischemia. While this logic is based on sound physiological concept, 2 the study did not actually demonstrate that this is true by comparing this protocol to a single-isotope, Tc-99m-based one. Thus, it remains mostly a feasibility study of a dual isotope protocol using low-dose thallium-201. In this respect, it is not exclusive, since such an approach has been proven feasible before. 3 In fact, like many similar studies of diagnostic performance, the manuscript leaves the reader with many unanswered questions:
1. Can the results of this study, generated in a small patient population (n = 54) with a high suspicion of CAD (already referred for coronary angiography) be extrapolated to a broad population of stable patients with known or suspected CAD? 2. Is the protocol effective in real-life situations? While comparative studies generally assess diagnostic accuracy parameters like sensitivity and specificity (efficacy) under controlled circumstances, how a test performs in real life (effectiveness) is important from a pragmatic standpoint. For example, studies show that CT coronary angiography (CTCA) has a higher negative predictive value than other imaging tests for CAD.
failure. Thus, most patients referred to stress SPECT imaging actually get it. 3. Is the higher radiation dose compared to a low-dose, single-isotope Tc-99m protocol justified by a higher diagnostic accuracy and more accurate quantification of myocardial ischemia? 4. Most importantly, does the choice of this protocol in preference to others have an impact on relevant outcome measures? In the current environment of value-based care, this is an important consideration. A case in point is the study by Siebelink and colleagues, comparing SPECT (stress/ rest Tc-99m sestamibi) and PET (N-13 NH3 and F-18 FDG) for viability assessment in 103 patients with moderate LV systolic dysfunction. While it is generally accepted that PET detects viability more efficiently than SPECT, this study showed that treatment allocation (revascularization vs. medical therapy alone) and patient outcome were not impacted by the choice of modality (SPECT or PET-based information provided to blinded treating physicians in random order). 5 Comparative studies of diagnostic tests should aim to demonstrate whether improvements in diagnostic performance translate into meaningful clinical advantage.
The last decade saw a profusion of comparative diagnostic imaging studies in stable CAD populations, resulting from burgeoning new diagnostic modalities and expanding applications of existing ones. Studies such as the current one by Barone-Rochette and colleagues provide important insights into the performance characteristics of diagnostic tests for stable CAD. However, to truly inform our management of patients in an additive manner, studies should be designed to provide information beyond just diagnostic accuracy.
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